Ramipril Capsule
Product Images NDC 51407-708

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Ramipril (NDC 51407-708). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Gsms, Incorporated, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemstructure (Chemstruc)

FDA Label Image

Containerlabel10 (Containerlabel10)

This text provides information about a medication in capsule form containing Ramipril, USP 10 mg. It includes dosage and administration details, a warning to keep out of reach of children, storage instructions, and manufacturing details. Marketed by GSMS, Incorporated and manufactured by CorePharma, LLC. The medication comes in a pack of 100 capsules.*

FDA Label Image

Containerlabel2point5 (Containerlabel2point5)

This is information related to Ramipril capsules, USP containing 2.5 mg of Ramipril per capsule. The prescription medication comes in a container with 100 capsules, and the dosage and administration details can be found in the package insert. It is important to keep this medication away from children and store it at a temperature between 20° to 25°C (68 to 77°F). The capsules should be dispensed in tight, light-resistant, child-resistant containers by pharmacists. The product is marketed by GSMS, Incorporated in Camarillo, California, and manufactured by CorePharma, LLC in Middlesex, New Jersey.*

FDA Label Image

Containerlabel5 (Containerlabel5)

This text is a product label for Ramipril Capsules, which contains 5 mg of Ramipril. It includes information on dosage, administration, warnings, storage instructions, and details of the manufacturer and marketer. The product is marketed by GSMS, Incorporated and manufactured by CorePharma, LLC.*

FDA Label Image

Figure1 (Figure1)

This is a chart showing the proportion of patients over 1000 days of follow-up. The proportions are given for different time intervals.*

FDA Label Image

Figure2 (Figure2)

This is a statistical data table showing the incidence of different outcomes in patients receiving placebo. The outcomes include cardiovascular disease, diabetes, age groups, gender, hypertension, history of coronary artery disease, prior myocardial infarction, cerebrovascular disease, peripheral vascular disease, and microalbuminuria. The table also includes the number of patients in each category and a column for the relative risk in the Ramipril group with a 95% confidence interval.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.